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The binding of Au(III) complexes to the zinc finger domain of the 
anticancer drug target PARP-1 was studied using a hyphenated 
mass spectrometry approach combined with quantum 
mechanics/molecular mechanics (QM/MM) studies. Competition 
experiments were carried out, whereby each Au complex was 
exposed to two types of zinc fingers. Notably, the cyclometallated 
Au-C^N complex was identified as the most selective candidate to 
disrupt the PARP-1 zinc finger domain, forming distinct adducts 
compared to the coordination compound Auphen. 
 
Zinc finger domains (ZFs) are relatively small protein structural 
motifs coordinating Zn2+ ions and functioning as recognition 
domains for nucleic acids or proteins. Proteins that contain 
zinc fingers are classified into several different structural 
families, playing important roles in cellular functions such as 
transcription, apoptosis, DNA repair and RNA packaging.1 A 
particular ZF domain is determined by its three-dimensional 
structure, but it can also be recognized based on the primary 
structure of the peptide or the identity of the ligands 
coordinating the Zn2+ ion. The latter are in general Cys2His2 
(CCHH), Cys2HisCys (CCHC) and Cys4-types (CCCC) domains. 
Notably, the respective protein functions dictate the 
coordination environment of zinc in the ZF domain. For 
example, while the zinc fingers of transcription factors involve 
mainly two cysteines and two histidines (CCHH) coordinating 
zinc, hormone receptors feature ZFs with four cysteines.2  
 ZF proteins have been shown to be involved in cancer 
progression, and some of them are promising therapeutic 
targets.3 For example, inhibition of the zinc finger protein 
poly(ADP-ribose)-polymerase-1 (PARP-1), essential in 
preserving genomic integrity4, 5 and involved in cisplatin 
resistance mechanisms,6 has been recently shown to be a 
successful strategy to treat cancers bearing BRCA1/2 
mutations.7 In fact, three PARP-1 inhibitors were approved 
over the last four years as chemotherapeutic agents targeting 
the catalytic NAD+ binding site.8 In humans, 17 PARP isoforms 
have been identified so far, all featuring a similar C-terminal 
catalytic domain9 and consequently, inhibitors of the catalytic 
function of PARP-1 can also interact with other isoforms,5 
leading to severe side effects.10 As an alternative strategy, 
since PARP-1 is the only isoform containing two N-terminal ZF 
domains,11 its selective inhibition may be achieved by 
disrupting the specific CCHC zinc finger domains and thereby, 
the protein–DNA interaction. 
 Within this framework, we have demonstrated the 
possibility to potently inhibit PARP-1 using Au(III) compounds 
targeting its ZF motif. Thus, both the coordination complex 
[Au(phen)Cl2]Cl (phen = 1,10-phenanthroline, Auphen)12 and 
the organometallic cyclometalated compound [Au(pyb-H)Cl2] 
(pyb = 2-benzylpyridine, Au-C^N)13 (Figure 1A) inhibited PARP-1 
in vitro at a nM level, which is an order of magnitude higher 
than that of the FDA-approved drug Olaparib (IC50 = 0.03 ± 0.01 
μM).14 Furthermore, we postulated a mechanism of inhibition 
by Auphen involving a transmetallation reaction, whereby Au3+ 
ions replace Zn2+ in the ZF, forming the so-called gold-finger,12 
and disrupting the DNA binding properties of PARP-1.  
 So far, gold-finger formation was mainly assessed by mass 
spectrometry (MS) techniques.2, 12, 15-17 Recently, Farrell et al. 
investigated the binding of coordination Au(III)/Au(I) 
complexes to the ZF of the HIV-nucleocapsid protein (NCp7) by 
high resolution and traveling-wave ion mobility mass 
spectrometry, respectively.17-19 Despite these encouraging 
results, doubts remain on the selectivity of anticancer Au(III) 
compounds for discriminating between CCHC over CCHH or 
CCCC coordination motifs, as such compounds were shown to 
interact with CCHH and CCCC zinc fingers alike, when 
incubated individually.2, 15 
  
Figure 1. A. Scheme of the four Au(III) complexes used in this study; B. Sequences of 
the CCHC (top) and CCHH (bottom) model peptides of zinc fingers (ZF-PARP and ZF-2, 
respectively). Arrows indicate the confirmed binding site of gold from the tandem mass 
spectrometry experiments.  
 Sampling the metallodrug binding selectivity for intact 
protein domains under “competitive” conditions - such as 
those encountered in a cellular context - represents a 
considerable experimental challenge,20 which is mainly caused 
by the difficulty of separating the intact reaction products, by 
potential ligand scrambling reactions and by redox reactivity 
during lengthy work-up and analysis. Thus, we report here on a 
rapid hyphenated mass spectrometry approach to assess: (i) 
the binding preference of representative Au(III) complexes 
towards the CCHC PARP-1-like zinc finger domain and (ii) the 
coordination sphere of gold ions upon binding to ZF domains.  
 To these aims, three representative cyclometalated Au(III) 
complexes featuring C^N and C^N^N type of ligands (Figure 
1A) were tested for their selectivity towards the CCHC ZF 
domains in comparison to Auphen. Interestingly, [Au(bipydmb-
H)(OH)][PF6] (bipydmb = 6-(1,1-dimethylbenzyl)-2,2’-bipyridine, 
Au-C^N^N) showed stability in physiological media and 
moderate cytotoxic activity towards both cisplatin-sensitive 
and resistant cancer cell lines.21 Moreover, [Au(phepya-H)Cl2] 
(phepya = N-phenylpyridin-2-amine, Au-CaN), also reported as 
a moderate cytotoxic agent,22 is structurally very similar to Au-
C^N. The MS analysis was carried out using peptide sequences 
of the N-terminal CCHC zinc finger domain of PARP-1 (ZF-PARP, 
44 amino acids, Figure 1B) previously used by us,12 and of the 
CCHH zinc finger as a model for transcription factors (ZF2, 26 
residues, Figure 1B),15 both reduced with dithiothreitol (DTT) 
and incubated with zinc acetate in (NH4)2CO3 buffer (25 mM, 
pH 7.4) in order to form the ZF motifs prior to exposure to the 
gold compounds. 
 Initially, individual experiments were carried out, whereby 
each gold complex was incubated separately with each type of 
ZF peptide in a 3:1 ratio (see Supporting Information, Figures 
S1-S4 and Tables S1-S4). The results showed that all 
compounds react quickly, but distinctively, with both types of 
ZF domains by displacing zinc from the coordination site. 
Overall, while Auphen forms gold-finger domains upon release 
of the phen ligand with both ZFs, the cyclometalated 
complexes mostly retain the C^N or C^N^N ligands stabilizing 
the Au(III) oxidation state in the resulting adducts. 
 A HPLC-ESI-MS method was then set up for performing the 
competition experiments. Each gold complex was assessed for 
its binding preference for one type of zinc finger motif when 
exposed to both CCHH and CCHC ZF peptides. To this end, each 
compound was shortly incubated with an equimolar mixture of 
ZF-PARP and ZF2. In order to reduce the probability of on-
column ligand exchange or possible demetalation reactions, a 
10 min linear gradient up to 95% MeCN was used and 
separation was performed using a C4 column (300 Å). The 
intact and unreacted ZF domains were well separated under 
these conditions and eluted at 3.08 min (ZF2) and 5.24 min 
(ZF-PARP), respectively (Figures S1 and S2). Thus, ZF2 was 
detected at m/z 494.5862 (mtheor = 494.5781, z = 6+) and ZF-
PARP was detected at m/z 732.5150 (mtheor = 732.5078, z = 7+).  
 The binding preference of the compounds towards ZF-
PARP over ZF2 was then calculated by assuming that the 
ionization efficiency of the gold-adducts, i.e. gold finger, is 
similar to the corresponding unreacted zinc finger. 
Percentages of gold-adduct formation are obtained for ZF-
PARP and ZF2 separately, by summing up the attributable peak 
areas obtained from the extracted ion chromatograms (EIC) of 
each unreacted ZF-domain and the respective interaction 
products (see experimental for details and Table S11). The 
affinity for gold binding to the ZF-PARP vs ZF2 is then 
expressed as a ratio of the two percentages for forming gold-
adducts, termed binding preference ratio (BPR). The higher the 
BPR for a given compound, the more pronounced is its affinity 
for ZF-PARP. Thus, the incubation of the mixture of both ZFs 
with Auphen revealed replacement of Zn by Au in the ZF 
domains next to unreacted ZF2 and ZF-PARP. The interaction 
product between Auphen and ZF2 was found at 3.26 min 
corresponding to [Apo-ZF2+AuI-H]6+ (Figures 2A and S5 and 
Table S5). At an elution time of 5.29 min, the mass spectrum 
obtained from the broad peak identified [Apo-ZF-PARP+AuI-
H]7+ as the main interaction product. A BPR of 29 in favour of 
ZF-PARP was obtained for Auphen.  
 The organometallic Au(III) complexes were tested in an 
analogous setting. Upon incubation of Au-C^N with an 
equimolar mixture of both peptides for 5 min, Apo-ZF2 was 
detected (elution at 3.11 min), as well as the corresponding 
adduct [Apo-ZF2+AuI-H]n+ at 3.26 min (Figures 2B, S6A and S6B 
and Table S6). Apo-ZF-PARP was detected at 5.26-5.48 min, 
while the main adducts were identified as [Apo-ZF-
PARP+AuIIIC^N-2H]7+ and [Apo-ZF-PARP+2[AuIIIC^N-2H]]7+ 
overlapping in time with the unreacted ZF-PARP (Figure S6B). 
Au-C^N showed the highest selectivity for the CCHC type of ZF 
with a BPR of 32, even though the gold organometallic reacts 
equally fast with both model peptides individually (Figures S3 
and S4). It should be noted that another peak was observed at 
4.96 min, identified as an adduct of the Au-C^N complex with 
DTT (Figure S6A).  
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Figure 2. A. Extracted chromatograms of the HPLC-ESI-MS analysis of the reaction of 
Auphen with ZF-PARP and ZF2 (3:1:1 ratio) after 5 min incubation at 37°C and 
corresponding mass spectra at 3.26 and 5.29 min; B. Extracted chromatograms of the 
HPLC-ESI-MS analysis of the reaction of Au-C^N with ZF-PARP and ZF2 (3:1:1 ratio) after 
5 min incubation at 37°C and corresponding mass spectra at 3.26 and 5.33 min. 
 In the competition experiment, whereby Au-CaN was 
incubated with both ZF2 and ZF-PARP, a new peak at 3.82 min 
indicated the presence of an adduct of the type [Apo-
ZF2+AuIIICaN-2H]n+ and confirming a different reactivity with 
respect to Au-C^N (Figure S7 and Table S7). The mass 
spectrum obtained from the broad peak at 5.28 min indicated 
the predominant presence of the Apo-ZF-PARP peptide, along 
with the corresponding adduct [Apo-ZF-PARP+AuIIICaN-2H]. 
Remarkably, the obtained results clearly showed that Au-C^N 
and Au-CaN, although structurally very similar, shows a low 
selectivity towards the CCHC type ZF (BPR of 2). 
 Finally, incubation of the Au-C^N^N complex resulted in 
the formation of adducts with both peptides (Figure S8 and 
Table S8) and selective towards the CCHC type of ZFs (BPR of 
10). Specifically, adducts eluting at 3.26 min were identified as 
mono- and bis-Au(I) adducts on Apo-ZF2, whereas [Apo-ZF-
PARP+AuIII-3H] and [Apo-ZF-PARP+AuIIIC^N^N-3H] were 
detected at 5.24 minutes, alongside Apo-ZF-PARP, in line with 
the individual experiments (Figures S3 and S4). Thus, although 
displacing Zn from the peptide, a monodentate binding mode 
to the ZF does not entail an appreciable gain in selectivity. 
 The second series of competition experiments was 
designed to evaluate the selectivity of Auphen and Au-C^N for 
the CCHC type of ZFs in presence of other proteins. 
Cytochrome c (cyt c), a small heme-containing protein, was 
selected for this study as a suitable model for LC-MS 
experiments.23, 24 Each gold complex was incubated with a 1:1 
mixture of ZF-PARP and cyt c for 5 min at 37°C and analysed 
using the same HPLC-ESI-MS set-up. In all cases, no gold 
adducts were observed with cyt c, whereas adducts with ZF-
PARP were identified as similar than in the individual 
experiments, i.e. Au(I) ions with Auphen and formation of 
[Apo-ZF-PARP+AuIII-C^N-2H] adducts with Au-C^N (Figures S9-
S10 and Tables S9-S10). Similar results were obtained replacing 
cyt c with another model protein, namely ubiquitin (data not 
shown). This result confirmed the selectivity of Auphen and 
Au-C^N for the CCHC type ZF, also in presence of other 
proteins and excludes purely non-selective coordination of the 
metal to surface-exposed and nucleophilic amino acids. 
 Tentative identification of the binding sites of the two most 
promising gold complexes (Auphen and Au-C^N) was then 
conducted using an online top-down approach. Fragmentation 
experiments by collision-induced dissociation (CID) were 
carried out on selected adducts from the individual or 
competition experiments, allowing the production of b and y 
ions fragments on both peptides and identification of the 
metallated residues. The isolated adducts corresponded to 
[Apo-ZF2+AuI-H] and [Apo-ZF-PARP+AuIII-3H] in the case of 
Auphen (Figures S3 and S4), and [Apo-ZF2+AuIIIC^N-2H] and 
[Apo-ZF-PARP+AuIIIC^N-2H] in the case of Au-C^N (Figures 2, 
S4 and S6). Figure S11 shows the identified metallated 
fragments and binding sites for each type of adduct. For [Apo-
ZF2+AuI-H], Cys4 (Figure 1B) was confirmed as the most stable 
Au-binding site. Furthermore, the presence of a y7 fragment 
suggested that one of the two histidine residues (His20 or 
His24, Figure 1B) might also be involved in coordinating the AuI 
ion. The fragmentation pattern of [Apo-ZF2+AuIIIC^N-2H] 
suggested a similar reactivity involving Au(C^N) coordinating 
to Cys4/7 and His24. On ZF-PARP, only b fragments were 
identified in both cases. The presence of a metallated b7 
fragment indicated that Cys5 (Figure 1B) was a binding site for 
the Au(I) ion of Auphen. In the case of Au-C^N, the first 
metallated fragment identified was b12, therefore suggesting 
Cys5 or Cys8 as likely binding sites. Complementary ion 
mobility mass spectrometry (IM-MS) studies were conducted 
to assess the structure of the gold finger in the case of Au-C^N 
(Figure S12) and suggest extensive unfolding of the peptide 
upon adduct formation as shown by the similar drift times as 
for the Apo-ZF-PARP in the applied experimental conditions. 
 To provide an atomistic support to the experimental 
results, DFT calculations have been performed to evaluate the 
binding energy of compounds Au-C^N, Au-CaN and Au-C^N^N 
(See SI for details). The obtained results (Figures S13-S16, 
Table S12) showed that the binding with cysteinato (Cys-), 
after substitution of one chlorido ligand, is highly preferred 
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compared to the binding with histidine, the latter being 
characterized by positive calculated energy values of adduct 
formation. Moreover, the binding of both Au-C^N and Au-CaN 
with two Cys- ligands is much stronger than that with only one 
Cys-, as in the case of the Au-C^N^N, or with two mixed Cys-
/His ligands. 
Figure 3. Gold finger formation. Example of the possible binding of Au-C^N with 
the zinc finger domain of PARP-1, in which two chlorido ligands of Au-C^N have 
been replaced by two cysteinato groups. Represented is the most stable 
structure among four isomers considered (see Figure S17) obtained by QM/MM 
calculations, after full geometry optimization. In the enlarged picture, the QM 
layer is highlighted in balls and sticks and the Au3+ ion as a yellow sphere. 
Drawings produced by the UCSF Chimera package.25 
 
Finally, the binding Au-C^N with two Cys- is also slightly 
stronger than that established by Au-CaN. These results 
prompted us to hypothesize a possible binding mechanism of 
Au-C^N with the zinc finger domain of PARP-1. QM/MM 
calculations (see SI for details) have been performed using the 
ZF-PARP model (PDB ID 2DMJ). By removing the zinc ion from 
the CCHC coordination site, it has been verified that Au-C^N 
can easily approach it in four different stereochemical isomers  
(Figures S17-S19). Specifically, the two accessible Cys residues, 
Cys8 and Cys40, can coordinate the Au3+ ion, while the C^N 
ligand remains outside the protein cavity (Figure 3). Instead, 
Cys5 is unlikely to bind gold, since this residue is more buried 
in the folded peptide. These results are in line with our top-
down analysis and those recently reported by Farrell et al. on 
the binding of an Au(I) complex to another CCHC ZF model.18 
 In summary, we have set-up a rapid hyphenated HPLC-ESI- 
MS approach to study the reactivity and selectivity of a series 
of Au(III) complexes towards model peptides of zinc fingers. 
The nature of the adducts formed were identified and showed 
that even though all gold complexes are very reactive towards 
both types of zinc fingers (CCHH and CCHC) individually, trends 
in selectivity can be drawn. Firstly, both the organometallic Au-
C^N compound and the coordination complex Auphen 
exhibited a significant selectivity for the PARP-1 ZF also in the 
presence of a CCHH type of ZF domain, representing a rather 
unique feature in the quest for selective PARP-1 inhibitors. 
Furthermore, the Au-C^N complex has been able of preserving 
the Au3+ oxidation state while retaining the C^N ligand upon 
binding to the most accessible Cys residues. Thus, leading to 
important alterations of the DNA recognition domain of PARP-
1 and eventually to protein inhibition.13,15 Notably, while 
Au(III) coordination complexes as Auphen have been 
previously shown to bind also to the membrane water and 
glycerol channels aquaporins, Au-C^N was scarcely reactive, 
thus, holding even more promise to selectively target ZF 
domains.26 Overall, targeting the structural DNA recognition 
domain of PARP-1 instead of the catalytic domain, similar in 
several PARP isoforms, appears as a promising strategy to 
increase the selectivity of PARP-1 inhibitors.  
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